comparemela.com

Latest Breaking News On - Corporate communications compugen - Page 1 : comparemela.com

Compugen Reports First Quarter 2023 Results

On track to deliver initial findings from studies with the triple blockade of PVRIG, TIGIT and PD-1 in patients with MSS CRC and platinum resistant ovarian.

San franciscoUnited statesTel avivYvonne naughtonStock exchangeCompugen ltdCorporate communications compugen ltdSecurities exchangeExchange commissionAnat cohen dayagChief executive officerSecurities actSecurities exchange actPrivate securities litigation reform actAnnual reportInvestor relations

Compugen Reports Third Quarter 2022 Results

New encouraging preliminary clinical data, presented at SITC 2022, showing anti-tumor activity supported by potent immune activation in the tumor.

Tel avivYvonne naughtonCorporate communications compugen ltdStock exchangeExchange commissionSecurities exchangePrnewswire compugen ltdAnat cohen dayagChief executive officerSouth san franciscoSecurities actSecurities exchange actPrivate securities litigation reform actAnnual reportInvestor relationsCorporate communications compugen

Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer

/PRNewswire/ Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today.

Israel generalTel avivAlberto sessaYvonne naughtonCorporate communications compugen ltdStock exchangeMaster of business administrationHebrew university of jerusalemWorldwide groupPrnewswire compugen ltdChief financial officerAnat cohen dayagChief executive officerBusiness administrationHebrew universitySouth san francisco

Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan

/PRNewswire/ Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today.

Tel avivYvonne naughtonCompugen ltdCorporate communications compugen ltdStock exchangeExchange commissionSecurities exchangeJapan patent officeAnat cohen dayagChief executive officerSouth san franciscoSecurities actSecurities exchange actPrivate securities litigation reform actAnnual reportInvestor relations

Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio

/PRNewswire/ Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today.

United statesTel avivYvonne naughtonEuropean patent officeCompugen ltdCorporate communications compugen ltdStock exchangeExchange commissionSecurities exchangePrnewswire compugen ltdAnat cohen dayagChief executive officerSouth san franciscoSecurities actSecurities exchange actPrivate securities litigation reform act

vimarsana © 2020. All Rights Reserved.